Case Report: Sequential treatment with rituximab and belimumab in a pediatric patient of type 1 diabetes mellitus complicated with systemic lupus erythematosus

病例报告:利妥昔单抗和贝利木单抗序贯治疗1型糖尿病合并系统性红斑狼疮的儿科患者

阅读:1

Abstract

Type 1 diabetes mellitus (T1DM) and systemic lupus erythematosus (SLE) are both autoimmune diseases influenced by multiple genetic and environmental factors, but rarely coexist. This case describes a 13-year-old girl with early onset of T1DM who was diagnosed with SLE 12 years later, highlighting diagnostic and therapeutic challenges, particularly in distinguishing kidney involvement and management without exacerbating hyperglycemia. The patient presented with edema of the eyelids and lower limbs. Urinalysis revealed hematuria and proteinuria. High-titer antinuclear antibody and anti-double-stranded DNA were detected. SLE was diagnosed clinically. As T1DM and SLE both cause kidney damage, kidney biopsy was performed. Deposition of various immune complexes led to a diagnosis of lupus nephritis. To avoid the impact of steroid pulses on glycemic control, conventional dose of steroids with sequential treatment with rituximab and belimumab was initiated. The combined therapy effectively alleviated the SLE condition, reduced steroids dosage, and led to discontinuation of steroids after 13 months. However, due to the prolonged disease course of T1DM, the pancreatic cell function was not reversed.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。